All In Biotech

Drug Trial Radar · NCT05972174

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

Phase 1/2, Randomized, Observer-Blind, Parallel, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults ≥18 Years of Age

Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,504 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,504

Actual

Start

Jul 10, 2023

Primary completion

Jul 16, 2024

Study completion Jul 16, 2024

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Aug 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial with one selected vaccine candidate. The study will be conducted in 2 Parts (Part A and Part B) that will enroll and run concurrently. Part A of the study will evaluate 4 vaccine candidates (H5N8, H7N9, H5 only, and H7 only). Part B of the study will evaluate a single vaccine candidate (H5 only-CG).

Conditions

  • Influenza

Interventions

  • mRNA-1018 for H5N8Biological

    Sterile liquid for injection

  • mRNA-1018 for H7N9Biological

    Sterile liquid for injection

  • mRNA-1018 for H5 OnlyBiological

    Sterile liquid for injection

  • mRNA-1018 for H7 OnlyBiological

    Sterile liquid for injection

  • mRNA-1018 for H5 Only-CGBiological

    Sterile liquid for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to Day 29 (7 days after each injection)
  2. Number of Participants with Unsolicited Adverse Events (AEs)Time frame: Up to Day 43 (21 days after each injection)
  3. Number of Participants with AEs Leading to Discontinuation From StudyTime frame: Day 1 to Day 205 (end of study [EoS])
  4. Number of Participants with Medically-Attended AEs (MAAEs)Time frame: Day 1 to Day 205 (EoS)
  5. Number of Participants with Serious Adverse Events (SAEs)Time frame: Day 1 to Day 205 (EoS)
  6. Number of Participants with Adverse Events of Special Interest (AESIs)Time frame: Day 1 to Day 205 (EoS)

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • CenExel RCA

    Hollywood, Florida

  • Velocity Clinical Research

    Savannah, Georgia

  • Johnson County Clin-Trials

    Lenexa, Kansas

  • DM Clinical Research

    Southfield, Michigan

  • Velocity Clinical Research

    Lincoln, Nebraska

  • Velocity Clinical Research Providence

    East Greenwich, Rhode Island

  • DM Clinical Research

    Sugar Land, Texas

  • DM Clinical Research

    Tomball, Texas

  • J. Lewis Research, Inc/Jordan River Family Medicine

    South Jordan, Utah

  • Western Hospital Edinburgh

    Edinburgh, United Kingdom

  • Royal Free Hospital

    London, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital

    London, United Kingdom

  • Chelsea and Westminster Hospital

    London, United Kingdom

  • St Georges Vaccine Institute Cranmer Terrace

    London, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Velocity Clinical Research

    North Finchley, United Kingdom

  • Royal Victoria Infirmary

    Newcastle upon Tyne, England, United Kingdom

  • Southampton General Hospital

    Southampton, England, United Kingdom

  • University Hospitals Birmingham

    Birmingham, London, United Kingdom

  • Bradford Teaching Hospitals NHS Foundation Trust

    Bradford, London, United Kingdom

  • University Hospitals

    Bristol, London, United Kingdom

  • Cardiff and Vale University

    Cardiff, London, United Kingdom

  • Northern Care Alliance

    Salford, London, United Kingdom

  • Royal Cornwall Hospital

    Truro, London, United Kingdom

  • North Wales Clinical Research Centre

    Wrexham, London, United Kingdom

  • Quadram Institute NNUH CRF

    Norwich, Norfolk, United Kingdom

  • Lakeside Healthcare Research Unit

    Corby, Northamptonshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.